Work Here?
About Revolution Medicines
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Overview
Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.
💡 Want to apply to Revolution Medicines?
You have ways to get a Revolution Medicines referral from your network.
Get referrals →
Simplify's Take
What believers are saying
- Acquisition of EQRx adds over $1 billion in capital for R&D.
- FDA fast-tracking supports their RAS-targeted therapy pipeline.
- Growing interest in targeted cancer therapies boosts investment opportunities.
What critics are saying
- EQRx acquisition may pose integration challenges and cultural clashes.
- $600M public stock offering could lead to shareholder dilution.
- Focus on RAS-addicted cancers limits market scope and increases competition risk.
What makes Revolution Medicines unique
- Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
- Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
- Exclusive license with University of Illinois enhances their unique synthesis technology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1286.3M
Above
Industry Average
Funded Over
4 Rounds
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 7%Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within
Corvex Management buys Illumina, exits Apple, TKO.
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders
On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.
Revolution Medicines is Hiring for 116 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Revolution Medicines
About Revolution Medicines
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Revolution Medicines is Hiring for 116 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Revolution Medicines